AngioDynamics, Inc. (NASDAQ:ANGO) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC raised its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 5.1% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 960,767 shares of the medical instruments supplier’s stock after purchasing an additional 46,409 shares during the period. Geode Capital Management LLC’s holdings in AngioDynamics were worth $7,477,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in ANGO. Barclays PLC boosted its position in shares of AngioDynamics by 81.0% in the 3rd quarter. Barclays PLC now owns 83,582 shares of the medical instruments supplier’s stock valued at $651,000 after purchasing an additional 37,394 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of AngioDynamics in the third quarter valued at approximately $280,000. XTX Topco Ltd acquired a new stake in shares of AngioDynamics in the third quarter valued at approximately $582,000. State Street Corp grew its position in shares of AngioDynamics by 2.7% during the third quarter. State Street Corp now owns 810,372 shares of the medical instruments supplier’s stock worth $6,305,000 after acquiring an additional 21,218 shares during the last quarter. Finally, Systematic Financial Management LP increased its holdings in shares of AngioDynamics by 14.3% in the 3rd quarter. Systematic Financial Management LP now owns 2,410,346 shares of the medical instruments supplier’s stock valued at $18,752,000 after acquiring an additional 300,785 shares during the period. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Canaccord Genuity Group decreased their price target on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, October 4th. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of AngioDynamics in a report on Tuesday, December 10th.

Insider Activity at AngioDynamics

In other AngioDynamics news, CEO James C. Clemmer acquired 20,000 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were purchased at an average price of $6.03 per share, with a total value of $120,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 681,582 shares of the company’s stock, valued at approximately $4,109,939.46. The trade was a 3.02 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders bought a total of 22,568 shares of company stock worth $135,847 over the last 90 days. Company insiders own 5.40% of the company’s stock.

AngioDynamics Stock Performance

Shares of ANGO opened at $8.98 on Friday. The stock has a market capitalization of $364.89 million, a P/E ratio of -1.47 and a beta of 0.68. AngioDynamics, Inc. has a 1 year low of $5.26 and a 1 year high of $9.58. The company’s fifty day moving average is $7.73 and its two-hundred day moving average is $7.21.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. The business had revenue of $67.50 million for the quarter, compared to the consensus estimate of $67.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The business’s quarterly revenue was down 14.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.12) earnings per share. Sell-side analysts predict that AngioDynamics, Inc. will post -0.41 EPS for the current year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.